Ansa Biotechnologies to Showcase Early Access Customer Success at Upcoming Global Synthetic Biology Conference
Customers around the world are now taking advantage of these services to develop critical advancements in therapeutics, vaccines, biomanufacturing, agriculture, and more.
- Customers around the world are now taking advantage of these services to develop critical advancements in therapeutics, vaccines, biomanufacturing, agriculture, and more.
- “Ansa is enabling a new wave of innovation in healthcare and life science research,” said Mr. Gammack.
- The program offers DNA sequences in both sequence-perfect clonal DNA or faster sequence-verified linear dsDNA fragment formats.
- To learn more about how to participate in the expanded early access program, visit ansabio.com/early-access .